U.S. FDA Warns Eisai’s Epilepsy Drug Could Risk Kidney, Bone Problems
This article was originally published in PharmAsia News
Executive Summary
Eisai's Zonegran (zonisamide) took a hit from U.S. FDA when the agency warned the epilepsy drug could increase the risk of kidney stones and bone disease. The drug, also sold as a generic, is approved for partial seizures in adult epilepsy patients in combination with other medications. FDA advised physicians Zonegran could cause metabolic acidosis, which leads to the other problems. The agency said it was requiring Eisai and generics makers to add the risk to a warning label, which would advise they be tested for the condition during treatment. (Click here for more - a subscription may be required